The first half of 2025 has brought major developments in gastroenterology, spanning new drug approvals, trial data, and clinical guidance. Two major FDA approvals expanded the use of IL-23-targeted therapies in Crohn’s disease: mirikizumab (Omvoh) and guselkumab (Tremfya), both showing strong clinical efficacy across trials.
Trending
- Evaluating the analytical performance of direct-to-consumer gut microbiome testing services (Nature)
- Resecting a Rectal Carcinoid (GI & Endoscopy News)
- AI blood test detects early pancreatic cancer with up to 94% accuracy (Medical Xpress)
- Why 2026 is a reset year for U.S. health care (Medical Economics)
- The “Dream Team” for Managing IBS-C Needs GI Psychologist and Dietician (Gastroenterology Learning Network)
- March 2026 issue Of The American Journal of Gastroenterology (The American Journal of Gastroenterology)
- The GI physician shortage by state, by 2036 (Becker’s GI & Endoscopy)
- PAGI Joins UPMC to Expand Access to Specialized Gastroenterology Care in Central Pa. (UPMC)
